Long-Acting Buprenorphine Versus Naltrexone Opioid Treatments in Criminal Justice System–Involved Adults
The NYU Langone hub of the National Institute on Drug Abuse (NIDA)’s Justice and Community Opioid Innovation Network is conducting a randomized controlled trial comparing the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) versus extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons in five states.
This open-label, non-inferiority, head-to-head study design will offer providers, correctional and public health authorities, payers, and policy makers' timely and relevant data to assess the effectiveness of long-acting buprenorphine versus naltrexone opioid treatments in criminal justice system-involved adults (EXIT-CJS) as potentially useful re-entry and relapse prevention treatment options. The NYU Langone hub is composed of research teams at Yale, Dartmouth, Oregon Health Science University, Friends Research Institute, and Rutgers Medical School.
This study is sponsored by the National Institute on Drug Abuse (NCT04219540).